AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Deal

Key Takeaways

• AbbVie will acquire Apogee Therapeutics in a cash transaction valued at approximately $10.9 billion, according to a news release.
• The acquisition brings late-stage IL-13 inhibitor zumilokibart and asthma candidate APG273 into the AbbVie inflammatory portfolio.

AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopic dermatitis (AD).

"Apogee's pipeline adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need, including AD and asthma," said Robert A. Michael, chairman and chief executive officer, AbbVie, in the news release. 

Under the terms of the agreement, Apogee shareholders will receive $135.11 per share in cash. The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter of 2026. The deal adds zumilokibart (APG777), a half-life extended monoclonal antibody targeting IL-13 currently in late-stage development for atopic dermatitis (AD). According to the companies, Phase 2 data show clinically meaningful improvements in skin clearance, itch reduction, and disease control, with approximately two-thirds of treated patients achieving significant skin clearance at 16 weeks. 

Atopic Dermatitis and Asthma Assets Drive Strategic Expansion

Apogee’s pipeline also includes APG273, a combination of zumilokibart and APG333, an anti-thymic stromal lymphopoietin (TSLP) antibody being developed for asthma. The companies highlighted the potential for extended dosing intervals based on early clinical data demonstrating prolonged suppression of type 2 inflammatory biomarkers.

"This transaction reflects the strength of Apogee's vision, our team's dedication and the significant progress we've made advancing zumilokibart and our differentiated pipeline," said Michael Henderson, MD, chief executive officer, Apogee, said in the press release. "Since our founding, we've focused on developing transformative therapies for patients with inflammatory diseases while creating value for shareholders. This transaction delivers substantial shareholder value and positions our programs to reach their full potential. We are deeply grateful to the patients, physicians and investigators who helped make this milestone possible. We believe AbbVie can advance zumilokibart and our portfolio while expanding their impact for patients worldwide."

Source

AbbVie press release, June 22, 2026.